journal article·2017-11-17Open access

In vitro assessment of non-irritant microemulsified voriconazole hydrogel system

Prasanna Raju Y, Hyndavi N, Harini Chowdary V, Rajesh S Nair, Jamal Basha D, Tejeswari N

Abstract

Research was aimed on microemulsion-based hydrogel for voriconazole. Oleic acid and isopropyl myristate as lipid phases; tween 20: tween 80 as surfactants and PEG600 as cosurfactant were selected to formulate voriconazole microemulsions. The promising microemulsions in terms of zeta potential, pH, viscosity, and drug release were selected and developed into hydrogels using carbopol 934. Resulting microemulsion-based hydrogel (MBH) of voriconazole were evaluated for in vitro diffusion and ex vivo permeation. Antifungal potentials of MBH were assessed against selected fungal strains. Optimal MBH formulations, O6 and O8 had displayed their antifungal potentials with enlarged zone of inhibition against selected fungal strains.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Antifungal resistance and susceptibility · Antimicrobial agents and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Pharmaceutics Division, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati, India;

Pharmaceutics Division, PES College of Pharmacy, Bangalore, India;

School of Pharmacy, The University of Nottingham Malaysia Campus, Jalan Broga, Semenyih, Selangor, Malaysia

References (38)

Show source-provided references
1. Bagwe RP · Crit Rev Ther Drug Carrier Syst · 2001 · 18 · 77
2. 10.3109/03639045.2014.89112910.3109/03639045.2014.891129 ↗
3. 10.1016/j.ijpharm.2006.02.01510.1016/j.ijpharm.2006.02.015 ↗
4. 10.1016/j.jconrel.2004.06.00110.1016/j.jconrel.2004.06.001 ↗
5. 10.1016/j.ijpharm.2007.03.05210.1016/j.ijpharm.2007.03.052 ↗
6. 10.1080/1071754050031310910.1080/10717540500313109 ↗
7. 10.1016/S0378-5173(97)00248-210.1016/S0378-5173(97)00248-2 ↗
8. 10.1086/32462010.1086/324620 ↗
9. 10.1208/s12249-015-0421-y10.1208/s12249-015-0421-y ↗
10. 10.1007/s11095-009-9956-510.1007/s11095-009-9956-5 ↗
11. 10.1016/j.ejpb.2008.08.01410.1016/j.ejpb.2008.08.014 ↗
12. 10.1016/j.ijpharm.2009.12.05010.1016/j.ijpharm.2009.12.050 ↗
13. 10.1208/s12249-015-0383-010.1208/s12249-015-0383-0 ↗
14. 10.1016/j.ijpharm.2004.11.03310.1016/j.ijpharm.2004.11.033 ↗
15. 10.3109/21691401.2013.85210110.3109/21691401.2013.852101 ↗
16. Harding VD. 2003. Pharmaceutical formulations containing voriconazole. Google Patents.
17. 10.1016/j.ejps.2010.03.00810.1016/j.ejps.2010.03.008 ↗
18. 10.1038/152102a010.1038/152102a0 ↗
19. 10.1016/S0149-2918(03)80126-110.1016/S0149-2918(03)80126-1 ↗
20. 10.1517/17425247.2010.52523010.1517/17425247.2010.525230 ↗
21. 10.1016/j.cis.2006.05.01410.1016/j.cis.2006.05.014 ↗
22. 10.1002/jps.2317810.1002/jps.23178 ↗
23. 10.1016/j.addr.2012.09.01810.1016/j.addr.2012.09.018 ↗
24. 10.1016/j.colsurfb.2010.08.01810.1016/j.colsurfb.2010.08.018 ↗
25. 10.2174/156720181266615021212450810.2174/1567201812666150212124508 ↗
26. 10.2174/15672018120615122811320910.2174/156720181206151228113209 ↗
27. Raj R · Artif Cells Nanomed Biotechnol · 2016 · 44 · 143410.3109/21691401.2015.1036997 ↗
28. 10.1016/S0378-5173(01)00827-410.1016/S0378-5173(01)00827-4 ↗
29. 10.1159/00014022810.1159/000140228 ↗
30. 10.1086/36793310.1086/367933 ↗
31. 10.1016/j.colsurfb.2011.05.04110.1016/j.colsurfb.2011.05.041 ↗
32. 10.1615/CritRevTherDrugCarrierSyst.v16.i5.2010.1615/CritRevTherDrugCarrierSyst.v16.i5.20 ↗
33. 10.1016/j.ejpb.2004.07.01110.1016/j.ejpb.2004.07.011 ↗
34. 10.1185/03007990312500188410.1185/030079903125001884 ↗
35. Ustundag Okur N · Int J Pharm · 2011 · 416 · 136
36. Xiao YY · Yao Xue Xue Bao · 2011 · 46 · 720
37. 10.3109/21691401.2015.112962210.3109/21691401.2015.1129622 ↗
38. 10.1016/j.ijpharm.2009.05.01910.1016/j.ijpharm.2009.05.019 ↗